NovoCure Limited · NASDAQ:NVCR

NovoCure — Investor Presentation (March 2016)

25 slides from NovoCure's investor presentation, Mar 1, 2016

  1. Slide 1: Novocure (NVCR) Overview

    Novocure (NVCR) Overview updated March 1, 2016 Actor Portrayal

  2. Slide 2: Notice

    Notice This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology indications. These fo

  3. Slide 3: Tumor Treating Fields

    Tumor Treating Fields Novel, anti-mitotic solid tumor cancer therapy Used as monotherapies or in combination to treat solid tumors for over 100 years Pharmacological Tumor Treating Surgery Radiation Treatments Fields • Most frequently • Kills cells when delivered • Includes chemotherapy, • Low-inten

  4. Slide 4: Frequency Tuned to Specific Cell Types

    Frequency Tuned to Specific Cell Types Treatment does not harm normal cell growth © Novocure 2016 4

  5. Slide 5: Non-invasive, Portable Delivery

    Non-invasive, Portable Delivery • Battery or wall-powered electric field generator • Single-use transducer arrays replaced 2-3 times a week © Novocure 2016 5

  6. Slide 6: Home Use, Quality of Life Maintained

    Home Use, Quality of Life Maintained • Should be used at least 18 hours a day • Mild side-effect profile with no known systemic toxicity Actor Portrayal © Novocure 2016 6

  7. Slide 7: Second Generation Optune System

    Second Generation Optune System • Half the size and weight of the first generation – only 2.7 pounds • CE marked and available in Europe • PMA supplement filed with FDA in December 2015 (180-day review) © Novocure 2016 7

  8. Slide 8: Extensive Preclinical Research

    Extensive Preclinical Research • 15+ years of research and multiple peer-reviewed publications • Deep understanding of the underlying mechanism © Novocure 2016 8

  9. Slide 9: Initial FDA Approval in 2011

    Initial FDA Approval in 2011 Monotherapy treatment for recurrent GBM Optune Chemotherapy (n=120) (n=117) Median OS, months 6.6 6.0 HR and p value HR=0.86, p=0.27 4-year survival 8% 0% Subgroup Analysis (p<0.05) FDA Approved Summary of Safety and Effectiveness Data “…NovoTTF-100A treatment exhibits m

  10. Slide 10: EF-14 Phase 3 Trial Initiated in 2009

    EF-14 Phase 3 Trial Initiated in 2009 Combination Therapy for Newly Diagnosed GBM A prospective, multicenter trial of TTFields together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM • 80 centers; 695 newly diagnosed GBM patients randomized 2:1 (TTFields plus T

  11. Slide 11: EF-14 Progression Free Survival

    EF-14 Progression Free Survival Intent-to-treat Population TTFields + TMZ TMZ alone (n=210) (n=105) Median PFS, months 7.2 4.0 HR and p value HR=0.62, p=0.001 © Novocure 2016 11

  12. Slide 12: EF-14 Overall Survival

    EF-14 Overall Survival As-treated Population TTFields + TMZ TMZ alone (n=196) (n=84) Median OS, months 20.5 15.6 HR and p value HR=0.66, p=0.004 2-year survival 48% 32% p value p=0.0058 © Novocure 2016 12

  13. Slide 13: FDA Approval on October 5, 2015

    FDA Approval on October 5, 2015 Combination treatment for newly diagnosed GBM © Novocure 2016 13

  14. Slide 14: Established Commercial Organization

    Established Commercial Organization • Recurrent GBM patients primarily treated in academic hospitals; early commercial efforts focused on neuro oncologists at academic centers • Estimate 60% of newly diagnosed GBM treated in community setting • U.S. sales team expanded in 2015 to reach community-bas

  15. Slide 15: Direct to Patient Distribution Model

    Direct to Patient Distribution Model Physician sends prescription order to Novocure Physician or Novocure uses NovoTAL System Physician economics to create array placement map • Physician can bill for incremental services Novocure delivers Optune to home • Physician does not and trains patient/famil

  16. Slide 16: Established Reimbursement History

    Established Reimbursement History • Nine U.S. payers have positive coverage covering >107 million people • Have secured coverage for approximately 98% of U.S. patients with commercial and privately-administered government plans • Appealing Medicare fee-for-service denials (20-25% of US patients) • P

  17. Slide 17: Novocure's Key Operating Statistics

    Novocure’s Key Operating Statistics Cash Filled Active Prescriptions Gross Billings Payments per Prescriptions Patients Month • Prescriptions - leading indicator of demand (counted only once per patient) • Conversion to new patients driven by fill rate and time to fill • 73% fill rate in 2015 • Rela

  18. Slide 18: Significant QoQ Active Patient Growth

    Significant QoQ Active Patient Growth Active patients drive revenues Global active patients at period end Oct. 2015 > 360% growth FDA approval Nov. 2014 EF-14 presentation U.S. certified centers 154 >175 >190 215 244 >300 U.S. sales colleagues 14 17 27 31 © Novocure 2016 18

  19. Slide 19: Selected Financial Data

    Selected Financial Data • Per U.S. GAAP, revenue is recognized when cash is collected • Cost of revenues reflects costs incurred for patients on Optune in the period U.S. dollars in thousands 2015 2014 % Growth Net revenues 33,087 15,490 114% Cost of revenues 20,610 10,036 105% Gross profit 12,477 5

  20. Slide 20: Total Addressable GBM Market >$2.5B

    Total Addressable GBM Market >$2.5B United States 12,500 GBM incidence 9,300 medically eligible Target EU Markets for treatment 13,500 GBM incidence Japan $1.2 Billion TAM 10,000 medically eligible 1,500 GBM incidence for treatment 1,100 medically eligible $1.3 Billion TAM for treatment $139 Million

  21. Slide 21: Broad Applicability to Solid Tumors

    Broad Applicability to Solid Tumors Indications In-vitro Evidence In-vivo Evidence First in Human Evidence Glioblastoma Malignant melanoma Non-small cell lung cancer Pancreatic cancer Breast cancer Mesothelioma Ovarian carcinoma Renal adenocarcinoma Cervical cancer Colorectal carcinoma Gastric adeno

  22. Slide 22: Multiple Ongoing Clinical Trials

    Multiple Ongoing Clinical Trials Phase 2 Phase 3 Pre clinical Pilot Pivotal Marketed Expected Next Milestone Indications Recurrent GBM with Optune Newly Diagnosed GBM Brain Metastases METIS trial first patient in 2016 NSCLC LUNAR trial first patient in 2016 Pancreatic Cancer PANOVA trial 2nd cohort

  23. Slide 23: Phase 2 EF-15 Trial

    Phase 2 EF-15 Trial Non-small cell lung cancer • Open label study (n=41) of TTFields at 150 kHz in combination with pemetrexed for advance non-small cell lung cancer • Trial results published in Lung Cancer1 in July 2013 TTFields with Pemetrexed-alone Efficacy endpoints pemetrexed historical control

  24. Slide 24: Phase 2 PANOVA Trial

    Phase 2 PANOVA Trial Pancreatic cancer • Open label study (n=20) of TTFields at 150 kHz with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma • Second cohort (n=20) of TTFields at 150 kHz with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adeno

  25. Slide 25: Anticipated 2016 Milestones

    Anticipated 2016 Milestones NCCN guidelines update Increase positive coverage policies of Optune Phase 2 pilot PANOVA trial 2nd cohort last patient in Phase 3 pivotal METIS trial first patient in Phase 3 pivotal LUNAR trial first patient in FDA approval of second generation device Newly diagnosed GB

Novocure — Investor Presentation (March 2016) on 6ix